Clinical trial monitoring is the process of overseeing the progress of a clinical trial to ensure that it is conducted, recorded, and reported in accordance with the protocol, GCP, and applicable regulatory requirements. Under ICH E6, monitoring is a core sponsor responsibility.
What Is Clinical Trial Monitoring?
Monitoring involves regular contact between the sponsor or its representatives — typically Clinical Research Associates (CRAs) — and the trial site to verify that investigator obligations are being fulfilled. Monitors conduct site visits to review source documents, verify informed consent procedures, check investigational product accountability, and confirm adverse event reporting. The frequency and intensity of monitoring visits depend on the trial’s complexity, risks, and enrollment rate.
Regulatory Framework
ICH E6 Section 5.18 provides detailed guidance on monitoring requirements, emphasizing risk-based monitoring as the preferred approach. The FDA and EMA support a shift from routine 100% source data verification toward targeted monitoring focused on critical data and processes. Sponsors must develop a monitoring plan that describes the monitoring strategy, responsibilities, and procedures.
Key Requirements
Monitors must be appropriately trained and qualified and must follow written Standard Operating Procedures (SOPs) . Each monitoring visit must be documented with a visit report that identifies any findings, deviations, or deficiencies and outlines corrective actions. The monitor must also verify that all serious adverse events are reported within the required timelines and that protocol amendments receive proper approval before implementation.
Documentation
Monitoring documentation includes the monitoring plan, visit reports, follow-up letters, and correspondence with the investigator. The monitor must confirm that the investigator maintains all essential documents in the Trial Master File (TMF) and that source data are accurate and complete. Monitoring visit reports become part of the sponsor’s TMF and may be reviewed during regulatory inspections.
Conclusion
Clinical trial monitoring is essential for ensuring data integrity and participant safety. A risk-based monitoring approach allows sponsors to focus resources on the most critical aspects of trial conduct. Effective monitoring requires clear communication between the sponsor, monitor, and investigator throughout the trial.
